Vyvanse Australia: PBS Cost & Prescribing Rules (2026)

If your prescriber has mentioned Vyvanse — or you've been taking it and want to understand it better — this guide covers everything from how it works and what it costs to what to do if your pharmacy runs out. Vyvanse (the brand name for lisdexamfetamine dimesylate) is the most commonly prescribed ADHD medication in Australia, approved by the TGA for children (aged 6+), adolescents, and adults.

How lisdexamfetamine works: Vyvanse is a prodrug — it is pharmacologically inactive in its original form. After you swallow the capsule, enzymes in your red blood cells gradually convert lisdexamfetamine into dexamfetamine (d-amphetamine), the active medication. This conversion process means:

• Slow, steady onset: Effects begin approximately 1-2 hours after taking the capsule and build gradually
• Long duration: 10-14 hours of symptom coverage from a single morning dose, compared to 3-5 hours for immediate-release dexamfetamine
• Lower abuse potential: Because the conversion happens in the body at a controlled rate, crushing, snorting, or injecting Vyvanse does not produce a rapid "high" — a key safety advantage over immediate-release stimulants
• Smoother effect profile: Most people experience fewer peaks and troughs compared to immediate-release formulations

Available strengths: 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg capsules. The capsules can be opened and the contents dissolved in water for people who have difficulty swallowing capsules — the prodrug mechanism is not affected.

• Typical dosing:**
• Starting dose: 30mg once daily in the morning (20mg for children or cautious titration)
• Titrated upward in 10-20mg increments at weekly or fortnightly intervals
• Maximum dose: 70mg per day (PBS maximum)
• Take in the morning with or without food. Taking it too late in the day can cause insomnia.

Vyvanse was first listed on the Australian PBS on 1 September 2015 for children and adolescents. PBS access was expanded on 1 February 2021 to include adults diagnosed with ADHD after age 18, a major milestone that removed one of the biggest barriers to treatment for late-diagnosed adults.

The cost of Vyvanse depends on whether you have PBS authority and your concession status.

With PBS authority (from 1 January 2026):

• Without PBS authority:**
• Approximately $120-$180 for 30 capsules depending on the pharmacy and strength
• This applies to private prescriptions or when PBS authority has not been obtained
• Annual cost without PBS: $1,440-$2,160

• How to get PBS-subsidised Vyvanse:**
• PBS authority is required for Vyvanse — your prescriber obtains this electronically when writing the script. The requirements are:
• ADHD diagnosed by a psychiatrist or paediatrician (or GP in QLD/SA)
• Confirmation that symptoms were present before age 12 (retrospective childhood onset is sufficient — you do not need a childhood diagnosis)
• The patient must have tried or be unsuitable for methylphenidate (for initial PBS authority) OR be continuing treatment previously initiated by a specialist

Important cost note: In December 2025, the PBS unit price for Vyvanse changed to $55 per unit across all strengths. This is the price the government pays the manufacturer — it does not change what you pay as a patient (the co-payment remains $25.00 general / $7.70 concession). However, it does affect the gap if you are paying privately.

Generic lisdexamfetamine: Generic versions of lisdexamfetamine are now available in Australia, which may reduce private prescription costs. The PBS co-payment is the same regardless of whether you receive brand-name Vyvanse or a generic.

For a complete overview of costs across all ADHD medications, see our ADHD medication guide. If you're new to the PBS system, our PBS guide explains how authority prescriptions, co-payments, and the Safety Net work.

This is one of the most confusing parts of ADHD treatment in Australia: who can actually write you a Vyvanse script depends on which state you live in. Here's the current picture as of February 2026:

What "GP continuation" means: A specialist (psychiatrist or paediatrician) initiates and stabilises the medication, then writes a letter to the GP authorising them to continue prescribing. The GP obtains their own PBS authority and writes ongoing scripts. This avoids the need for ongoing specialist appointments purely for script renewals.

Telehealth prescribing: Vyvanse can be prescribed via telehealth, but Schedule 8 prescribing via telehealth requires compliance with regulations in both the prescriber's state and the patient's state. Some states restrict interstate telehealth prescribing of Schedule 8 medications.

PBS authority process: Your prescriber calls or uses the electronic system to obtain a PBS authority number. This is recorded on the prescription and is required for the pharmacist to dispense at the subsidised price. The process takes a few minutes and is done at the time of prescribing — there is no extra cost or delay for the patient.

For detailed prescribing information across all ADHD medications, see our guide on ADHD medication in Australia. For state-specific GP prescribing, see our guides for Queensland, South Australia, NSW, Victoria, and Western Australia.

Most side effects of Vyvanse are dose-related and tend to be most noticeable during the first 2-4 weeks or after dose increases. Many settle as your body adjusts.

• Common side effects (experienced by >10% of patients):**
• Decreased appetite — the most common side effect. Appetite typically returns in the evening as the medication wears off. Strategies: eat a good breakfast before the medication kicks in, have a substantial dinner, keep calorie-dense snacks available.
• Insomnia/difficulty falling asleep — take Vyvanse early in the morning (before 8am). If sleep remains problematic, discuss with your prescriber — the dose may be too high, or the timing may need adjustment.
• Dry mouth — stay hydrated, sugar-free gum can help
• Headache — usually settles within the first 1-2 weeks

• Less common side effects (1-10%):**
• Increased heart rate (small increase, typically 5-10 bpm — clinically insignificant for most people)
• Mild blood pressure increase
• Anxiety or irritability (often dose-related — may indicate the dose is too high)
• Nausea or stomach discomfort (taking with food can help)
• Jitteriness or feeling "wired" (usually indicates the dose is too high)

End-of-dose effects: Some people experience a "crash" or rebound as Vyvanse wears off in the late afternoon/evening — irritability, mood dip, or return of ADHD symptoms. This is less pronounced with Vyvanse than with immediate-release stimulants due to its gradual offset, but it can still occur. Strategies include a small dose of immediate-release dexamfetamine in the afternoon (prescribed by your clinician) or adjusting the Vyvanse dose.

• Monitoring requirements (AADPA guideline):**
• Heart rate and blood pressure before starting, at each dose change, then every 6 months
• ECG is not routinely required unless there is a personal or family history of cardiac conditions
• Height and weight monitoring in children at each review
• Routine blood tests are not required unless clinically indicated

When to contact your prescriber immediately: Chest pain, palpitations, shortness of breath, severe anxiety or panic, hallucinations, or suicidal thoughts. These are rare but require prompt medical attention.

Understanding how Vyvanse compares to other ADHD medications available in Australia helps you have an informed discussion with your prescriber.

Amphetamine vs methylphenidate class: These are the two main stimulant classes. Approximately 70% of people respond well to either class, but some respond to one and not the other. If Vyvanse (amphetamine class) is ineffective or causes intolerable side effects, switching to methylphenidate (Ritalin/Concerta) is the standard approach, and vice versa. When both classes are tried sequentially, response rates reach 80-90%.

• Why Vyvanse is often preferred:**
• Single morning dose provides all-day coverage (simplicity)
• Prodrug mechanism makes it harder to misuse
• Smooth onset and offset with fewer peaks and troughs
• Well-studied in both children and adults

• When an alternative may be better:**
• If Vyvanse lasts too long and causes insomnia, a shorter-acting formulation may be preferable
• If cost is a major concern and PBS access is not available, immediate-release dexamfetamine may be more affordable
• If there is a history of substance use disorder, non-stimulant options (Strattera, Intuniv) may be considered first
• If anxiety is a significant comorbidity, atomoxetine may be preferred (though AADPA guidelines note stimulants are generally safe with anxiety — see our guide on ADHD and anxiety)

Vyvanse has been subject to periodic TGA shortage notifications, and the broader ADHD medication supply chain has been under significant pressure since 2023.

• Current shortage status (February 2026):**
• Vyvanse/lisdexamfetamine: Supply has generally stabilised following the introduction of generic lisdexamfetamine. Specific strengths may be intermittently unavailable at individual pharmacies.
• Concerta (methylphenidate OROS): Shortage notification extended through end of 2026. This is the most significantly affected ADHD medication in Australia.
• Ritalin LA: Intermittent supply issues continue.
• Dexamfetamine IR and Ritalin 10 IR: Generally available but can have localised shortages.

Why shortages are happening: ADHD medication dispensing in Australia increased dramatically — from 8 per 1,000 people in 2018-19 to 22 per 1,000 in 2023-24, an 11-fold increase from the 2004 baseline. Globally, demand has surged for similar reasons. Manufacturing capacity has not kept pace.

• What to do if your Vyvanse is unavailable:**
• Ask your pharmacist to check stock at nearby pharmacies or order from their wholesaler
• Generic lisdexamfetamine may be available when brand-name Vyvanse is not — ask your pharmacist
• Contact your prescriber about temporary alternatives:
• - Immediate-release dexamfetamine (same active metabolite as Vyvanse, just shorter-acting — requires multiple daily doses)
• - Methylphenidate-based alternatives if switching class is appropriate
• Do not stop medication abruptly — work with your prescriber to manage any transition
• AADPA dose conversion guidance: If switching between formulations, your prescriber can use published conversion tables. As a rough guide, Vyvanse 30mg is approximately equivalent to dexamfetamine IR 10mg daily (in divided doses).

TGA actions: The TGA has approved emergency importation of overseas-registered products under Section 19A of the Therapeutic Goods Act and convened a Methylphenidate Medicine Shortage Action Group. These measures have helped stabilise supply for the most critically affected medications.

Future outlook: The introduction of generic lisdexamfetamine has improved supply resilience for Vyvanse specifically. However, ongoing demand growth means intermittent shortages may continue across the broader ADHD medication market through 2026. For comprehensive shortage information, see our ADHD medication shortage guide.